Partner

Von der Michael J. Fox Foundation finanzierte Projekte
1. Oligomer Toxicity Inhibition in Synucleinopathies (OTIS):
Evaluation of the oligomer modulator anle138b in a seeding-based primate model of PD (started April 2014)
https://www.michaeljfox.org/grant/evaluation-oligomer-modulator-anle138b-seeding-based-model-parkinsons-disease

2. Oligomer Toxicity Inhibition in Synucleinopathies (OTIS):
Preclinical development of the oligomer modulator anle138b and establishment of a novel seeding-based biomarker (started October 2015)
https://www.michaeljfox.org/grant/pre-clinical-development-oligomer-modulator-anle138b-and-establishment-novel-seeding-based

3. Development of Selective Markers for Imaging Abnormal Protein Aggregates in Parkinson’s Disease
https://www.michaeljfox.org/grant/development-selective-markers-imaging-abnormal-protein-aggregates-parkinsons-disease

4. Anle138b Clinical Phase 1 Studies: Food Effect, Safety and Tolerability as well as Pharmacokinetics in Parkinson´s Disease Patients
https://www.michaeljfox.org/grant/anle138b-clinical-phase-1-studies-food-effect-safety-and-tolerability-well-pharmacokinetics

MultISyn EU Konsortium Multimodale Bildgebung von seltenen Synukleinopathien
Novel PET-tracers to link protein aggregation pathology to functional read-outs in animal models and in the corresponding human patient populations
http://www.multisyn.eu/team.php

The Cure Parkinson's Trust
https://www.cureparkinsons.org.uk/

ARTEMIS Research Association
http://www.erare.eu/financed-projects/artemis